113 related articles for article (PubMed ID: 18827376)
21. [Development of Novel Functional Formulations Based on Pharmaceutical Technologies].
Itai S
Yakugaku Zasshi; 2019; 139(3):419-435. PubMed ID: 30828022
[TBL] [Abstract][Full Text] [Related]
22. Assessment of the bioequivalence of two formulations of clarithromycin extended-release 500-mg tablets under fasting and fed conditions: a single-dose, randomized, open-label, two-period, two-way crossover study in healthy Jordanian male volunteers.
Alkhalidi BA; Tamimi JJ; Salem II; Ibrahim H; Sallam AA
Clin Ther; 2008 Oct; 30(10):1831-43. PubMed ID: 19014838
[TBL] [Abstract][Full Text] [Related]
23. Factors affecting solubility and penetration of clarithromycin through gastric mucus.
Grübel P; Cave DR
Aliment Pharmacol Ther; 1998 Jun; 12(6):569-76. PubMed ID: 9678818
[TBL] [Abstract][Full Text] [Related]
24. Clarithromycin suspension: bioequivalence studies on two different strengths.
Koytchev R; Ozalp Y; Erenmemisoglu A; van der Meer MJ; Alpan RS
Arzneimittelforschung; 2004 Sep; 54(9A):594-9. PubMed ID: 15497666
[TBL] [Abstract][Full Text] [Related]
25. Expedited Development of Diphenhydramine Orally Disintegrating Tablet through Integrated Crystal and Particle Engineering.
Wang C; Hu S; Sun CC
Mol Pharm; 2017 Oct; 14(10):3399-3408. PubMed ID: 28825961
[TBL] [Abstract][Full Text] [Related]
26. Taste masking analysis in pharmaceutical formulation development using an electronic tongue.
Zheng JY; Keeney MP
Int J Pharm; 2006 Mar; 310(1-2):118-24. PubMed ID: 16431048
[TBL] [Abstract][Full Text] [Related]
27. Formulation and development of oral dry suspension using taste masked Ornidazole particles prepared using Kollicoat(®) Smartseal 30 D.
Chivate A; Sargar V; Nalawade P; Tawde V
Drug Dev Ind Pharm; 2013 Jul; 39(7):1091-7. PubMed ID: 22900982
[TBL] [Abstract][Full Text] [Related]
28. [Preparation and evaluation of enteric-coated and taste masking clarithromycin granules].
Zhang T; Wang CR; Shen S; Jin Y; Ge YR
Yao Xue Xue Bao; 2011 Dec; 46(12):1520-5. PubMed ID: 22375429
[TBL] [Abstract][Full Text] [Related]
29. In vitro disintegration studies of weekly generic and branded risedronate sodium formulations available in Canada.
Walker AD; Adachi JD
Curr Med Res Opin; 2011 Sep; 27(9):1749-54. PubMed ID: 21781014
[TBL] [Abstract][Full Text] [Related]
30. Silica coatings on clarithromycin.
Bele M; Dmitrasinovic D; Planinsek O; Salobir M; Srcic S; Gaberscek M; Jamnik J
Int J Pharm; 2005 Mar; 291(1-2):149-53. PubMed ID: 15707741
[TBL] [Abstract][Full Text] [Related]
31. Preparation of polymer-blended quinine nanocomposite particles by spray drying and assessment of their instrumental bitterness-masking effect using a taste sensor.
Taki M; Tagami T; Ozeki T
Drug Dev Ind Pharm; 2017 May; 43(5):715-722. PubMed ID: 27401130
[TBL] [Abstract][Full Text] [Related]
32. Characteristics and evaluation of an injectable clarithromycin lipid-based complex in vitro and in vivo.
Ma Y; Li H; Guan S
Drug Deliv; 2013 Nov; 20(8):349-55. PubMed ID: 24032596
[TBL] [Abstract][Full Text] [Related]
33. Suppression of bitterness and improvement of palatability of commercial prednisolone powder.
Ishizaka T; Okada S; Tokuyama E; Mukai J; Uchida T
Chem Pharm Bull (Tokyo); 2008 Oct; 56(10):1395-9. PubMed ID: 18827377
[TBL] [Abstract][Full Text] [Related]
34. Formulation and thermal sterile stability of a less painful intravenous clarithromycin emulsion containing vitamin E.
Lu Y; Wang Y; Tang X
Int J Pharm; 2008 Jan; 346(1-2):47-56. PubMed ID: 17640833
[TBL] [Abstract][Full Text] [Related]
35. Capacity of cholesteryl hemisuccinate in ion pair/phospholipid complex to improve drug-loading, stability and antibacterial activity of clarithromycin intravenous lipid microsphere.
Luo L; Chen Q; Gong H; Liu L; Zhou L; He H; Zhang Y; Yin T; Tang X
Colloids Surf B Biointerfaces; 2018 Dec; 172():262-271. PubMed ID: 30173093
[TBL] [Abstract][Full Text] [Related]
36. Sensory properties of ginseng solutions modified by masking agents.
Tamamoto LC; Schmidt SJ; Lee SY
J Food Sci; 2010 Sep; 75(7):S341-7. PubMed ID: 21535568
[TBL] [Abstract][Full Text] [Related]
37. Inhalable Clarithromycin Microparticles for Treatment of Respiratory Infections.
Dimer F; de Souza Carvalho-Wodarz C; Haupenthal J; Hartmann R; Lehr CM
Pharm Res; 2015 Dec; 32(12):3850-61. PubMed ID: 26113237
[TBL] [Abstract][Full Text] [Related]
38. New co-spray-dried tobramycin nanoparticles-clarithromycin inhaled powder systems for lung infection therapy in cystic fibrosis patients.
Pilcer G; Rosière R; Traina K; Sebti T; Vanderbist F; Amighi K
J Pharm Sci; 2013 Jun; 102(6):1836-1846. PubMed ID: 23568616
[TBL] [Abstract][Full Text] [Related]
39. Bitterness evaluation of acidic pharmaceutical substances (NSAIDs) using a taste sensor.
Yoshida M; Haraguchi T; Uchida T
Chem Pharm Bull (Tokyo); 2014; 62(12):1252-8. PubMed ID: 25450633
[TBL] [Abstract][Full Text] [Related]
40. Formulation and evaluation of reconstitutable suspensions containing ibuprofen-loaded Eudragit microspheres.
Devrim B; Bozkir A; Canefe K
Acta Pol Pharm; 2011; 68(4):593-9. PubMed ID: 21796942
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
